Amicus Therapeutics Inc (FOLD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amicus Therapeutics Inc (FOLD) has a cash flow conversion efficiency ratio of 0.059x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($16.25 Million) by net assets ($274.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Amicus Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Amicus Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Amicus Therapeutics Inc debt and liabilities for a breakdown of total debt and financial obligations.
Amicus Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amicus Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Shenling Environmental Systems Co. Ltd.
SHE:301018
|
0.040x |
|
Companhia de Saneamento Básico do Estado de São Paulo - SABESP
SA:SBSP3
|
0.074x |
|
AAC Technologies Holdings Inc
F:A2XN
|
0.043x |
|
China First Heavy Industries
SHG:601106
|
0.073x |
|
360 ONE WAM LIMITED
NSE:360ONE
|
-0.169x |
|
BARRATT DEVEL. UNSP.ADR/2
F:3BAA
|
N/A |
|
CENTESSA PHARMACEUTICALS
F:260
|
N/A |
|
First Financial Bankshares Inc
NASDAQ:FFIN
|
0.041x |
Annual Cash Flow Conversion Efficiency for Amicus Therapeutics Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Amicus Therapeutics Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Amicus Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $274.24 Million | $33.15 Million | 0.121x | +169.20% |
| 2024-12-31 | $194.04 Million | $-33.89 Million | -0.175x | +59.51% |
| 2023-12-31 | $160.17 Million | $-69.09 Million | -0.431x | +68.14% |
| 2022-12-31 | $123.05 Million | $-166.57 Million | -1.354x | -105.49% |
| 2021-12-31 | $307.37 Million | $-202.49 Million | -0.659x | +19.13% |
| 2020-12-31 | $286.38 Million | $-233.29 Million | -0.815x | -54.98% |
| 2019-12-31 | $476.43 Million | $-250.42 Million | -0.526x | +39.91% |
| 2018-12-31 | $342.91 Million | $-299.95 Million | -0.875x | -43.23% |
| 2017-12-31 | $352.85 Million | $-215.49 Million | -0.611x | -46.11% |
| 2016-12-31 | $360.15 Million | $-150.53 Million | -0.418x | -45.18% |
| 2015-12-31 | $347.83 Million | $-100.14 Million | -0.288x | +31.92% |
| 2014-12-31 | $122.18 Million | $-51.67 Million | -0.423x | +57.75% |
| 2013-12-31 | $45.75 Million | $-45.79 Million | -1.001x | -105.33% |
| 2012-12-31 | $69.22 Million | $-33.74 Million | -0.487x | +70.81% |
| 2011-12-31 | $29.59 Million | $-49.42 Million | -1.670x | -675.56% |
| 2010-12-31 | $64.93 Million | $-13.98 Million | -0.215x | +64.33% |
| 2009-12-31 | $71.83 Million | $-43.37 Million | -0.604x | -16.36% |
| 2008-12-31 | $71.04 Million | $-36.86 Million | -0.519x | -452.81% |
| 2007-12-31 | $103.30 Million | $15.19 Million | 0.147x | -66.36% |
| 2006-12-31 | $-77.52 Million | $-33.89 Million | 0.437x | -13.57% |
| 2005-12-31 | $-35.83 Million | $-18.12 Million | 0.506x | -- |
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha … Read more